Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

NCT02158507 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Triple Negative Breast Cancer

Interventions

DRUG: Combination of Veliparib + Lapatinib

Sponsor

University of Alabama at Birmingham

Collaborators

[object Object]
[object Object]
[object Object]